|
MegaPro Medical’s new MRI contrast agent MPB-2043 has completed the first patient admission in Taiwan
|
2024-12-19 |
|
MegaPro (6827)’s new drug MPB-2354 issues a press release on WMIS
|
2024-10-23 |
|
MegaPro (6827) MPB-1734 completes the phase 1 of the last patient, press release
|
2024-10-23 |
|
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
|
2024-10-23 |
